Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3Peripheral Blood Stem Cell Transplantation 2Cyclosporins 2Cyclosporine 2Cyclophosphamide 2venetoclax 1ruxolitinib 1letermovir 1ibrutinib 1fludarabine 1carmustine, poliferprosan 20 drug combination 1Tacrolimus 1Stem Cell Transplantation 1Sirolimus 1Mitoxantrone 1Melphalan 1Lisaftoclax 1Hematopoietic Stem Cell Transplantation 1Etoposide 1Cytarabine 1Carmustine 1Biopsy 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Prolymphocytic, T-Cell × Lisaftoclax × Clear all
NCT04496349 2025-11-04

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Ascentage Pharma Group Inc.

Phase 2 Recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡